Develops precision genetic medicines and therapies focused on Cystic Fibrosis, Primary Ciliary Dyskinesia and various cancers and central nervous system diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/18/2024 | Series A-3 | $15MM | $xx.xx | $582.08MM | Amgen, Bayer, Cf Foundation, Colt Ventures, Ecor1 Capital, Hunt Technology Ventures, Matrix Capital Management, Mpm Capital, Ns Investment, Orbimed, Osage University Partners, Pfizer Ventures, Sanofi Ventures, Superstring Capital, Tekla Capital Management, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
1,252,854
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen, Bayer, Cf Foundation, Colt Ventures, Ecor1 Capital, Hunt Technology Ventures, Matrix Capital Management, Mpm Capital, Ns Investment, Orbimed, Osage University Partners, Pfizer Ventures, Sanofi Ventures, Superstring Capital, Tekla Capital Management, Vida Ventures
|
||||||
11/18/2024 | Series B | $274.8MM | $xx.xx | $582.08MM | Amgen, Bayer, Cf Foundation, Colt Ventures, Ecor1 Capital, Hunt Technology Ventures, Matrix Capital Management, Mpm Capital, Ns Investment, Orbimed, Osage University Partners, Pfizer Ventures, Sanofi Ventures, Superstring Capital, Tekla Capital Management, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
29,762,097
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen, Bayer, Cf Foundation, Colt Ventures, Ecor1 Capital, Hunt Technology Ventures, Matrix Capital Management, Mpm Capital, Ns Investment, Orbimed, Osage University Partners, Pfizer Ventures, Sanofi Ventures, Superstring Capital, Tekla Capital Management, Vida Ventures
|
||||||
03/26/2020 | Series A-4 | $5.36MM | $xx.xx | $160.84MM | Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
1,851,927
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures
|
||||||
03/26/2020 | Series A-5 | $5.32MM | $xx.xx | $160.84MM | Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
1,407,617
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures
|
||||||
03/26/2020 | Series A-1 | $80MM | $xx.xx | $160.84MM | Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
14,296,176
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Colt Ventures, Hunt Technology Ventures, Mpm Capital, Orbimed, Osage University Partners, Vida Ventures
|
||||||
12/16/2016 | Series A-2 | $2.08MM | $xx.xx | $4.63MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,126,512
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|